Cubist Systematic Strategies LLC Acquires Shares of 206,920 Immatics (NASDAQ:IMTX)

Cubist Systematic Strategies LLC acquired a new stake in Immatics (NASDAQ:IMTX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm acquired 206,920 shares of the company’s stock, valued at approximately $2,404,000. Cubist Systematic Strategies LLC owned about 0.24% of Immatics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. boosted its holdings in Immatics by 324.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,548,909 shares of the company’s stock valued at $16,310,000 after purchasing an additional 1,183,860 shares during the period. Wellington Management Group LLP boosted its holdings in Immatics by 13.3% in the 4th quarter. Wellington Management Group LLP now owns 6,352,929 shares of the company’s stock valued at $66,896,000 after purchasing an additional 747,772 shares during the period. Wasatch Advisors LP bought a new position in Immatics in the 1st quarter valued at $7,676,000. Nan Fung Group Holdings Ltd bought a new position in Immatics in the 1st quarter valued at $165,000. Finally, Affinity Asset Advisors LLC boosted its holdings in Immatics by 75.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 350,000 shares of the company’s stock valued at $3,678,000 after purchasing an additional 150,000 shares during the period. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Trading Down 0.1 %

IMTX stock opened at $9.34 on Friday. The firm’s 50-day moving average price is $11.41 and its two-hundred day moving average price is $11.48. Immatics has a 12-month low of $7.15 and a 12-month high of $13.77. The stock has a market capitalization of $790.72 million, a price-to-earnings ratio of -10.49 and a beta of 0.75.

Immatics (NASDAQ:IMTX) last announced its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.17. The firm had revenue of $20.19 million for the quarter, compared to analyst estimates of $12.36 million. Immatics had a negative net margin of 103.99% and a negative return on equity of 23.34%. Equities analysts predict that Immatics will post -0.94 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on IMTX shares. Piper Sandler started coverage on shares of Immatics in a report on Monday, October 7th. They set an “overweight” rating and a $19.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immatics in a report on Thursday, September 5th.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.